A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC
Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy and safety of SBRT combined with Puterizumab immunotherapy for non-small cell lung cancer with pulmonary metastases, and to determine the correlation between MRD and treatment efficacy. Through single-cell sequencing and spatial transcriptome information analysis, the underlying mechanisms will be analyzed to provide a basis for improving the new precision treatment methods for tumor immunotherapy resistance.